Literature DB >> 27315347

Early clinical experience with a new preloaded one-piece intraocular lens in paediatric cataract surgery.

D B Gosling1, T K J Chan1.   

Abstract

PurposeTo report the clinical experience of using the Tecnis PCB00 (Abbott Medical Optics, Santa Ana, CA, USA) preloaded one-piece intraocular lens (IOL) in the setting of a tertiary referral centre for paediatric cataract.MethodsA retrospective case note review of all paediatric cataract surgeries using the Tecnis PCB00 IOL, at a single UK paediatric ophthalmology department.ResultsNine eyes in seven patients received the IOL between December 2014 and January 2016. All patients underwent lens aspiration and insertion of the IOL 'in the bag.' The indications for surgery included developmental cataract (8/9) and traumatic cataract (1/9). Mean age at the time of surgery was 7 years (range 2-14). The median improvement in logMAR best-corrected visual acuity was 0.475 (range 0.250-1.500). The mean follow-up duration was 5 months (range 1-13). No operative or post-operative complications occurred as a result of using the device.ConclusionThe Tecnis PCB00 preloaded IOL appears to be a safe and effective device in treating paediatric cataract.

Entities:  

Mesh:

Year:  2016        PMID: 27315347      PMCID: PMC5023798          DOI: 10.1038/eye.2016.123

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  2 in total

1.  An 8-year retrospective study of cataract surgery and postoperative endophthalmitis: injectable intraocular lenses may reduce the incidence of postoperative endophthalmitis.

Authors:  Kelly Weston; Rory Nicholson; Catey Bunce; Yit Fung Yang
Journal:  Br J Ophthalmol       Date:  2015-04-13       Impact factor: 4.638

2.  Intraindividual comparative analysis of capsule opacification after implantation of 2 single-piece hydrophobic acrylic intraocular lenses models: Three-year follow-up.

Authors:  Guenal Kahraman; Michael Amon; Clara Ferdinaro; Karl Nigl; Michael Walch
Journal:  J Cataract Refract Surg       Date:  2015-05-05       Impact factor: 3.351

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.